Lokesh Ganesh L, Wang Hongyu, Lam Curtis H, Thiviyanathan Varatharasa, Ward Nancy, Gorenstein David G, Volk David E
Institute of Molecular Medicine for the Prevention of Human Diseases, The University of Texas Health Science Center, 1825 Pressler Street, Houston, TX, 77030, USA.
Department of Nanomedicine and Biomedical Engineering, McGovern Medical School, The University of Texas Health Science Center, 1825 Pressler Street, Houston, TX, 77030, USA.
Methods Mol Biol. 2017;1632:151-174. doi: 10.1007/978-1-4939-7138-1_10.
Aptamers and second generation analogs, such as X-Aptamers (XAs), SOMAmers, locked nucleic acids (LNAs), and others are increasingly being used for molecular pathway targeting, biomarker discovery, or disease diagnosis by interacting with protein targets on the surface of cells or in solution. Such targeting is being used for imaging, diagnostic evaluation, interference of protein function, or delivery of therapeutic agents. Selection of aptamers using the original SELEX method is cumbersome and time-consuming, often requiring 10-15 rounds of selection, and provides aptamers with a limited number of functional groups, namely four bases of DNA or RNA, although newer SELEX methods have increased this diversity. In contrast, X-Aptamers provide an unlimited number of functional groups and thus are superior targeting agents. Here, we discuss the X-Aptamer selection process.
适体和第二代类似物,如X-适体(XAs)、SOMAmers、锁核酸(LNA)等,正越来越多地用于分子途径靶向、生物标志物发现或疾病诊断,它们通过与细胞表面或溶液中的蛋白质靶点相互作用来实现。这种靶向作用被用于成像、诊断评估、蛋白质功能干扰或治疗剂递送。使用原始的指数富集的配体系统进化技术(SELEX)方法筛选适体既繁琐又耗时,通常需要进行10至15轮筛选,并且所提供的适体具有有限数量的官能团,即DNA或RNA的四个碱基,尽管更新的SELEX方法增加了这种多样性。相比之下,X-适体提供了无限数量的官能团,因此是更优异的靶向剂。在此,我们讨论X-适体的筛选过程。